Treating depression in Alzheimer's disease: Integration of differing guidelines

Marnina Swartz, Yoram Barak, Ilona Mirecki, Simona Naor, Abraham Weizman

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The developments in the understanding of Alzheimer's disease (AD) have led to genetic testing, expansion of research centers, and emergence of novel treatment modalities. However, behavioral symptoms and disturbances remain the leading cause of distress to families and patients. The management of these disturbances is not fully elucidated and not without controversies. Aim: To review and integrate the two important approaches to management and treatment of depression in AD as published in the American Psychiatric Association's guidelines for the treatment of patients with AD versus the American Academy of Neurology's official publication on managing AD. Method: Both publications are analyzed focusing on the pharmacological treatment of depression. The analysis includes sources of data, generalization, and common and conflicting recommendations. Conclusion: Selective serotonin reuptake inhibitors are the drugs of choice for the treatment of depression in AD patients.

Original languageEnglish
Pages (from-to)353-358
Number of pages6
JournalInternational Psychogeriatrics
Volume12
Issue number3
DOIs
StatePublished - 2000

Fingerprint

Dive into the research topics of 'Treating depression in Alzheimer's disease: Integration of differing guidelines'. Together they form a unique fingerprint.

Cite this